Notably, genetic and pharmacologic inhibition of key molecules that regulate CM hypertrophy pathways, such as calcineurin (CaN), have shown promise in blocking pathological hypertrophy and its progression to HF.22 The gene discussed is NUP214; the disease is hydrops fetalis.